Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helio S Sader

Showing results (141-150 of 420) with videos related to

Pageof 42
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 21, 2012
AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United StatesMichael A Pfaller, David J Farrell, Helio S Sader, et al.
Journal of Clinical Microbiology|January 13, 2004
Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp: report from the SENTRY Antimicrobial Surveillance Program (1997-2001)Jeffrey T Kirby, Helio S Sader, Timothy R Walsh, et al.
Diagnostic Microbiology and Infectious Disease|March 16, 2005
Reproducibility of gemifloxacin and comparison fluoroquinolone MIC results using Sensititre commercial dry-form panelsJames E Ross, Helio S Sader, Thomas R Fritsche, et al.
Antimicrobial Agents and Chemotherapy|January 9, 2008
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infectionsThomas R Fritsche, Paul R Rhomberg, Helio S Sader, et al.
International Journal of Antimicrobial Agents|November 23, 2006
Occurrence of plasmidic AmpC type beta-lactamase-mediated resistance in Escherichia coli: report from the SENTRY Antimicrobial Surveillance Program (North America, 2004)Lalitagauri M Deshpande, Ronald N Jones, Thomas R Fritsche, et al.
International Journal of Antimicrobial Agents|January 24, 2007
Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum StudyJames E Ross, Thomas R Fritsche, Helio S Sader, et al.
Antimicrobial Agents and Chemotherapy|June 28, 2006
Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocciRonald N Jones, Thomas R Fritsche, Helio S Sader, et al.
Antimicrobial Agents and Chemotherapy|October 2, 2013
Daptomycin activity against uncommonly isolated streptococcal and other gram-positive species groupsHelio S Sader, Robert K Flamm, David J Farrell, et al.
The Journal of Antimicrobial Chemotherapy|December 6, 2005
Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nationsRonald N Jones, James E Ross, Thomas R Fritsche, et al.
The Journal of Antimicrobial Chemotherapy|March 28, 2015
Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13)Helio S Sader, David J Farrell, Robert K Flamm, et al.
Pageof 42

Showing results (141-150 of 420) with videos related to

Sort By:
Pageof 42
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 21, 2012
AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United StatesMichael A Pfaller, David J Farrell, Helio S Sader, et al.
Journal of Clinical Microbiology|January 13, 2004
Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp: report from the SENTRY Antimicrobial Surveillance Program (1997-2001)Jeffrey T Kirby, Helio S Sader, Timothy R Walsh, et al.
Diagnostic Microbiology and Infectious Disease|March 16, 2005
Reproducibility of gemifloxacin and comparison fluoroquinolone MIC results using Sensititre commercial dry-form panelsJames E Ross, Helio S Sader, Thomas R Fritsche, et al.
Antimicrobial Agents and Chemotherapy|January 9, 2008
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infectionsThomas R Fritsche, Paul R Rhomberg, Helio S Sader, et al.
International Journal of Antimicrobial Agents|November 23, 2006
Occurrence of plasmidic AmpC type beta-lactamase-mediated resistance in Escherichia coli: report from the SENTRY Antimicrobial Surveillance Program (North America, 2004)Lalitagauri M Deshpande, Ronald N Jones, Thomas R Fritsche, et al.
International Journal of Antimicrobial Agents|January 24, 2007
Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum StudyJames E Ross, Thomas R Fritsche, Helio S Sader, et al.
Antimicrobial Agents and Chemotherapy|June 28, 2006
Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocciRonald N Jones, Thomas R Fritsche, Helio S Sader, et al.
Antimicrobial Agents and Chemotherapy|October 2, 2013
Daptomycin activity against uncommonly isolated streptococcal and other gram-positive species groupsHelio S Sader, Robert K Flamm, David J Farrell, et al.
The Journal of Antimicrobial Chemotherapy|December 6, 2005
Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nationsRonald N Jones, James E Ross, Thomas R Fritsche, et al.
The Journal of Antimicrobial Chemotherapy|March 28, 2015
Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13)Helio S Sader, David J Farrell, Robert K Flamm, et al.
Pageof 42